Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-

-Transaction to add near-term commercial opportunity to Jazz’s pipeline-

Read more at globenewswire.com